Business Context and Reporting Period
Krystal Biotech, Inc. (Nasdaq: KRYS) is a commercial-stage biotechnology company focused on genetic medicines using a proprietary HSV-1 vector platform. The filing covers the fiscal year ended December 31, 2025. The Company's primary commercial product is VYJUVEK (beremagene geperpavec-svdt), approved for the treatment of dystrophic epidermolysis bullosa (DEB) in the United States (2023), the European Union (April 2025), and Japan (July 2025). Commercial launches occurred in Germany (August 2025) and France and Japan (October 2025).
Key Financial Metrics
| Metric (in millions) | 2025 | 2024 | 2023 |
|---|---|---|---|
| Product Revenue, Net | $389.1 | $290.5 | $50.7 |
| Gross Margin | 94% | 93% | 94% |
| Operating Income | $161.3 | $65.7 | ($109.6) |
| Net Income | $204.8 | $89.2 | $10.9 |
| Diluted EPS | $6.84 | $3.00 | $0.39 |
| Cash, Cash Equivalents & Short-term Investments | $827.8 | $597.5 | N/A |
| Net Cash Provided by Operating Activities | $200.9 | $123.4 | ($88.8) |
Note: 2023 Net Income included a one-time $100 million gain from the sale of a Priority Review Voucher (PRV). 2024 included a $37.5 million litigation settlement expense.
Material Changes vs. Prior Period
- Revenue Growth: Net product revenue increased 34% year-over-year to $389.1 million, driven by expanded VYJUVEK sales in the U.S. and new international launches in Germany, France, and Japan.
- Profitability: Operating income more than doubled to $161.3 million, and Net Income increased 130% to $204.8 million. This was significantly aided by a $15.4 million income tax benefit resulting from the release of a valuation allowance on deferred tax assets.
- Expense Trends:
- Cost of Goods Sold (COGS): Increased to $23.0 million due to higher sales volume, partially offset by manufacturing process optimizations.
- R&D Expenses: Increased to $58.0 million, primarily due to expanded clinical trials for KB707 (oncology) and increased payroll.
- Selling, General & Administrative (SG&A): Increased to $146.7 million, driven by marketing costs for global commercialization and professional services.
- One-Time Items: Unlike 2023 (PRV sale) and 2024 (litigation settlement), 2025 had no litigation settlement expenses or PRV gains.
Guidance, Outlook, and Risks
Outlook and Pipeline Progress:
- VYJUVEK: Pricing negotiations are ongoing in Germany (expected H2 2026) and France (expected 2027). Italy launch is targeted for H2 2026.
- KB407 (Cystic Fibrosis): Positive interim data from Phase 1 Cohort 3 announced Jan 2026. Registrational study (CORAL-3) enrollment expected H1 2026.
- KB707 (Oncology): Prioritized for inhaled formulation in NSCLC. A new cohort evaluating combination with chemotherapy is ongoing; interim data expected in 2026.
- KB803 (Ocular DEB): Phase 3 IOLITE study enrollment expected to complete H1 2026; results later in 2026.
- KB801 (Neurotrophic Keratitis): Received FDA Platform Technology Designation (Oct 2025). Registrational study EMERALD-1 ongoing; data expected 2026.
Risks and Contingencies:
- Regulatory & Pricing: Success depends on favorable pricing and reimbursement outcomes in Europe and Japan. Delays in pricing negotiations could impact revenue timing.
- Manufacturing: The Company is transferring VYJUVEK manufacturing from the ANCORIS facility to the new ASTRA facility; delays in FDA approval of this transfer could impact supply.
- Legal: The Company is cooperating with a DOJ subpoena regarding its sponsored genetic testing program. A stockholder derivative suit regarding director compensation is in settlement negotiations.
- Cybersecurity: A 2024 incident at a specialty pharmacy provider delayed reimbursements; the Company notes ongoing risks to operations and data security.
Investor Verification Checklist
- International Pricing: Verify the status and expected outcomes of pricing negotiations in Germany and France, as these are critical for near-term revenue growth outside the U.S.
- Manufacturing Transfer: Confirm the timeline for FDA approval of the technical transfer of VYJUVEK production to the ASTRA facility to ensure no supply disruptions.
- DOJ Inquiry: Monitor developments regarding the Department of Justice subpoena related to the sponsored genetic testing program for potential financial or reputational impact.
- Tax Benefit Sustainability: Assess the sustainability of the 2025 tax benefit derived from the release of the valuation allowance, as this was a significant driver of net income.
- Pipeline Milestones: Track the initiation of the CORAL-3 (KB407) and IOLITE (KB803) studies in 2026 as key value inflection points.